# Airsculpt Technologies Airsculpt Technologies is an Asset Manager based in Miami Beach, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Miami Beach, United States - **Region:** North America - **Address:** Miami Beach, FL, United States - **Founded:** 2019 - **Assets under management:** Undisclosed - **Website:** airsculpt.com ## Regulatory record - **Reports private funds:** No ## About Dr. Aaron Rollins founded Airsculpt Technologies in 2019 after patenting an awak e liposuction method that eliminates general anesthesia, dramatically reducing downtime, cost, and surgical risk. The firm went public via a SPAC merger in 2021. Rollins — who remains the largest shareholder — built the company on a direct-to-consumer marketing engine that funnels patients into company-owned centers rather than licensing the technology to third-party surgeons. Airsculpt operates a concentrated portfolio of approximately 25 clinic locations across the U.S., each functioning as a standalone profit center. Revenue derives entirely from self-pay cosmetic procedures, with zero reliance on insurance reimbursement — a structural feature that insulates the business from payer dynamics. The flagship AirSculpt procedure targets the abdomen, arms, thighs, and chin. In 2023, the firm opened centers in Dallas, Texas and McLean, Virginia, expanding beyond its Florida base. The company reports same-store sales growth rather than fund-level IRRs, consistent with its architecture as an operator rather than a capital allocator. As of the end of 2023, the firm employed over 200 staff, including a dedicated in-house sales team that handles patient consultations. The corporate structure includes no adjacent investment vehicles, philanthropic foundations, or co-investor clubs. Dennis Dean serves as CFO, having joined in 2021 with a background in consumer services. September 2023: The company announced plans to repurchase up to $20 million of its own stock, signaling management's view that the public market undervalued the operating footprint. Airsculpt's structural differentiator is its inversion of the traditional private equity playbook: rather than raising a blind-pool fund and acquiring clinics, the firm expanded de novo, built the brand, and sold equity to public markets. The result is a balance sheet with no limited partners, no capital calls, and no GP clawback risk — but full exposure to consumer discretionary spending on elective procedures. ## Sectors - Healthcare Services ## People - Aaron Rollins — Founder & Chief Executive Officer - Dennis Dean — Chief Financial Officer ## Questions ### Who runs investment decisions at Airsculpt Technologies? The firm does not operate as a traditional investment vehicle with a CIO or investment committee. Capital allocation decisions — principally center openings and stock buybacks — are made by CEO Aaron Rollins and CFO Dennis Dean. Rollins remains the controlling shareholder, and all growth has been organic rather than via acquisition. ### How does Airsculpt source new clinic locations? Airsculpt selects markets based on demographics that indicate high demand for elective cosmetic procedures, using a direct-to-consumer marketing funnel to generate patient leads before committing to a lease. This approach minimizes upfront capital risk relative to acquiring existing practices. The firm does not franchise or license its technology. ### Why is Airsculpt structured as a public company rather than a private equity-backed chain? Aaron Rollins chose a SPAC merger in 2021 to access permanent capital and provide liquidity for early investors while retaining operational control. The public structure gives the firm a currency for acquisitions if it ever chooses to pursue them, though to date expansion has been entirely de novo. ### Is Airsculpt reliant on insurance reimbursement or is it entirely self-pay? All Airsculpt procedures are elective and paid for out-of-pocket by patients. The firm has zero exposure to insurance reimbursement rates, Medicare/Medicaid, or third-party payer authorizations. This self-pay model carries high margins but makes patient demand highly sensitive to consumer confidence and disposable income trends. ### Does Airsculpt participate in any private investment funds or co-investment vehicles? No. Airsculpt is an operating company, not an asset manager. It does not manage outside capital, participate in club deals, or invest in third-party funds. All capital deployed goes into the company's own clinic expansion, share repurchases, or corporate overhead. ### What is the firm's posture on franchising or licensing the AirSculpt technology? Airsculpt has consistently declined to franchise or license its technology to third-party surgeons. All procedures are performed by Airsculpt-employed physicians at company-owned centers. This vertical integration preserves brand control, pricing power, and quality consistency but limits the speed of geographic expansion. ## Related profiles - [OTG Acquisition Corp. I](https://altss.com/profile/otg-acquisition-corp-i) - [High Templar Tech](https://altss.com/profile/high-templar-tech-ltd) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/airsculpt-technologies-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology